Skip to main content

HA491

Product Details
WHO Product ID
HA491
Status
Prequalified
INN, dosage form and strength
Ritonavir Tablet, Film-coated 100mg
Date of prequalification
Basis of listing
Prequalification - Abridged
Therapeutic area
HIV/AIDS
Type
Finished Pharmaceutical Product
Dosage form
Tablet, Film-coated
Reference authority
European Medicines Agency
Applicant organization
AbbVie Deutschland GmbH and Co. KG
Knollstrasse 67061, Ludwigshafen
Germany
Packaging details and storage conditions
Packaging Type
Bottle, HDPE
Configuration
30x1; 60x1
Shelf life (months)
24
Storage conditions
Do not store above 30°C, protect from moisture
API Manufacturing Site(s)
By Organization
By Active Ingredient
AbbVie S.r.L
S.R. 148 Pontina, Km 52 snc
Campoverde di Aprilia (LT),
4011
Italy
Ritonavir
FPP Manufacturing Site(s)
AbbVie Deutschland GmbH and Co. KG
Knollstrasse 67061, Ludwigshafen
Germany
WHO Public Assessment Reports


Part 1 - Abstract
Part 2 - All accepted presentations (including photo)
Part 3 - WHO-PQ recommended patient information leaflet*
Part 4 - WHO-PQ recommended summary of product characteristics*
Part 5 - Label
Part 6 - Discussion (status at the time of prequalification)
Part 7 - Steps before Prequalification
Part 8 - Steps following Prequalification (from 01 March 2014, only changes to the published information are included)

* This summary of product characteristics/patient information leaflet focus on uses of the medicine covered by WHO Prequalification Team - Medicines. The recommendations for use are based on WHO guidelines and on information from stringent regulatory authorities (term to be revised). The medicine may be authorised for additional or different uses by national medicines regulatory authorities. 

 

Part 1 , Part 2 , Part 7

.